Peptide Comparability Analytics: What to Compare After a Process Change

Process changes are common in peptide development: a new synthesis site, purification resin, scale, container, formulation, or analytical method can alter the material. Comparability is the disciplined question of whether the change created a meaningful difference in attributes relevant to quality, safety, performance, or stability.

Start with the change map

Describe what changed, why it changed, what could be affected, and what evidence already exists. A minor equipment change may need a narrower package than a new manufacturing site or formulation. The plan should cover identity, purity and impurities, higher-order or physical properties where relevant, potency or function, and stability. The exact panel should follow the risk assessment rather than a fixed checklist.

Statistical comparisons need context. Overlapping means, a passing assay, or a familiar chromatogram does not prove interchangeability. Conversely, a small analytical difference may be acceptable if it is understood and does not affect the intended quality profile. Scientists should define acceptance logic before unblinding results to reduce hindsight bias.

Operations

Comparability generates many linked artifacts: change control, sample map, method versions, raw data, deviations, statistical outputs, and conclusion memo. A coordinator can keep those links intact across internal and contract labs. Quality and technical leads remain accountable for the conclusion.

Scope note

This is a research framework. It does not determine regulatory reporting obligations for a specific product or change.